US status

Compoundable

Section 503A lets a licensed pharmacy compound a drug for an individual patient with a valid prescription, drawing on bulk substances the FDA has nominated for its interim list. Category 1 of that list holds substances under review without identified safety concerns; pharmacies may compound them while the review continues.

Category 1 is a permission during review, not an approval, and it can end. The molecules below hold that position today, each verified on the date shown; sermorelin adds a stronger foundation, since it was itself an approved drug withdrawn for commercial rather than safety reasons.

Molecules holding this status

Sermorelin Compoundable (503A): Previously approved (Geref), discontinued in 2008 for business reasons; compounded today under 503A.
NAD+ Compoundable (503A): Category 1 of the interim 503A bulks list; compoundable with a valid prescription while FDA evaluates.
Glutathione Compoundable (503A): Category 1 of the interim 503A bulks list; compoundable with a valid prescription.

The pending page tracks six peptides that a July 2026 advisory vote recommended adding to this list; none has crossed yet.